Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LC Bead LUMI is a directly image-able, inherently radiopaque embolic agent composed of sulfonate-modified polyvinyl alcohol (PVA) hydrogel microbeads with covalently bound iodine (~260 mg I/ml). Developed by BTG (now Boston Scientific), it is designed for the transarterial embolization (TAE) of hypervascular liver tumors, including hepatocellular carcinoma (HCC) and neuroendocrine tumors. The beads provide mechanical occlusion of the blood vessels supplying the tumor, while their radiopacity allows for real-time feedback and geographic localization during the procedure using fluoroscopy, digital subtraction angiography (DSA), and cone-beam CT (CBCT). This visibility assists interventional radiologists in ensuring complete coverage of the target lesion and identifying potential areas of under-treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LC Bead LUMI.